Galectin Therapeutics Inc 2025财年普通股股东应占净亏损达3100万美元,合每股亏损0.48美元

美股速递
Mar 31

Galectin Therapeutics Inc(股票代码:GALT)公布的2025财年财务数据显示,公司全年普通股股东应占净亏损为3100万美元,折合每股亏损0.48美元。这一业绩反映了公司在研发阶段的持续投入以及运营成本的管理情况。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10